(Date:11/24/2009)...of debate. A high-profile study a few years ago su...arbon from trees and leaves, evidence for a very c...ystems. , But new research from the University o...Algae provide a much richer diet for fish and othe...is week in the Proceedings of the National Academ...
(Date:11/23/2009)...ed strain of the deadly superbug MRSAan infection-...icsposes a far greater health threat than previous...ording to a study in the December issue of Emergi...sily picked up in fitness centers, schools, and ot...rden of MRSA within hospitals, the report found. ,...
(Date:11/23/2009)...ants gathered this week for the seventh annual Nat.... This year,s topic, "Synthetic Biology," brought ...chers to explore the engineering, scientific, and ...nthetic biology. , Bonnie L. Bassler, professor ...his year,s conference chair, challenged the attend...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 1Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 2Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 3Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 4Gersten Savage Expands IP Practice With Partner Jason Lief 58308 1Gersten Savage Expands IP Practice With Partner Jason Lief 58308 2Oncolytics Biotech 28R 29 Inc Announces Reovirus and Cisplatin Research Supports U S Phase 2 Metastatic Melanoma Trial 14269 1Oncolytics Biotech 28R 29 Inc Announces Reovirus and Cisplatin Research Supports U S Phase 2 Metastatic Melanoma Trial 14269 2(Date:11/24/2009)... , , Primary efficacy endpoint has been m...nt endometrial cancer, , QUEBEC CITY, Nov. 24...ASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global...erapy and oncology, today announced positive effic...totoxic peptide conjugate, AEZS-108 (formerly AN-1...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-First...e global specialty biopharmaceutical company, toda...opean Medicines Agency for,velaglucerase alfa, the...nt,for the treatment of Type 1 Gaucher disease. Th...erase alfa that has been submitted, with previous,...
(Date:11/24/2009)... , REDWOOD CITY, Calif., Nov. 24 /PRNewswir...X ) today announced that Randy Scott, Genomic Heal...Annual Piper Jaffray Health Care Conference in New....m. ET. ,, To access the live and subsequently...nvestor Relations section of Genomic Health,s webs...
(Date:11/24/2009)... Program Connects Customers w...les Collected with DNA Genotek Products , ...009 -- DNA Genotek , a leading provider of produc... and preparation, today announced its new global p...ancements for DNA Genotek,s partner community and ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3...nc. , a designer and manufacturer of disk drives f...g completion of a 70,000 square foot plant additio...,Following its completion next month, Hutchinson w...ing developed by company engineers, and will tenta...arly 2007. , ,Connie Pautz, director of corporate ...
... the Governor,s Business Plan Contest, the Grand P...ge of its respective industry. This year,s field o... that continues the trend begun by start ups like ...evelopment and NovaScan, who tied for first in 200...ed on the first day of the annual Wisconsin Entrep...
... doctor may be losing a patient, but a significant...ironment of a hospital, there are hundreds of supp...e - a process that often leaves doctors rooting ar...ng from room to room in the hunt for a defibrillat... medical officer at BearingPoint, the hunt for sup...
Other Biology Technology:Hutchinson plant expansion nears completion 2Business plan finalists offer peek into entrepreneurial future 2Business plan finalists offer peek into entrepreneurial future 3RFID system aids hospital in tracking assets 2RFID system aids hospital in tracking assets 3Rabbit Anti-Human IRF7 Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Human Retinoic Acid-Induced 3 (RAI3 / RAIG1) Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-Human CD164 Antibody, Biotin Conjugated from BioLegend
Biology Products: